Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
NCT Number: NCT01642446
There is no consensus about the optimal treatment of hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, While this group of patients are classified as hepatectomy contraindication according to guidelines from National Comprehensive Cancer Network (NCCN) and American Association for the Study of Liver Diseases (AASLD). With improvement of surgical technique, preoperative evaluation, and perioperative management,especially the Precise Hepatectomy Technique, more and more studies confirmed the safety of surgical intervention to hepatocellular carcinoma (HCC) patients with cirrhotic portal hypertension.However, most of the previous studies were either retrospective or with small samples.
The investigators project is a prospective randomized controlled trial, planning to compare the safety, efficacy and quality of life between precise hepatectomy and combined interventional treatment on hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, to make a further understanding of optimal strategy.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Guangzhou, Guangdong, 510060, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Precise hepatectomy
transcatheter hepatic arterial chemoembolization and/or ablation
Time frame: 5 years
Overall survival is based on death from any cause, not just the condition being treated, thus it picks up death from side effects of the treatment, and effects on survival after relapse
Time frame: 90 days
defined as complications within the 90 days after treatment
Time frame: 3 years
TTP: The Hazard Ratio will be analyzed respectively with 95% confidence interval. Meanwhile, Kaplan-Meier estimation and survival curves will be performed.
Time frame: 3 years
Disease control rate: Calculate the disease control rate of the two treatment groups (disease control rate) and its 95% confidence interval, and make a descriptive analysis.
Time frame: 5 years
Quality of life: Follow the QOL-LC V2.0
Sun Yat-sen University
Other
A Randomized Control Clinical Trial Between Precise Hepatectomy and Combined Interventional Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06893887
Adenocarcinoma, Carcinoma
Nanjing, Jiangsu, China
View Trial DetailsNCT00593528
Cirrhotic Portal Hypertension, Digestive System Diseases
Bordeaux, France
View Trial DetailsNCT06265272
Adenocarcinoma, Carcinoma
Charlestown, Massachusetts, United States
View Trial DetailsNCT06594744
Adenocarcinoma, Carcinoma
Taipei, Taiwan
View Trial Details